Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00054717
Status:
COMPLETED
Last Update Posted:
2014-07-02
First Post:
2003-02-07
Brief Title:
Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir RESIST
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
Randomized Open-label Comparative Safety and Efficacy Study of Tipranavir Boosted With Low-dose Ritonavir TPVRTV Verses Genotypically-defined Protease InhibitorRitonavir PIRTV in Multiple Antiretroviral Drug-experienced Patients
Status:
COMPLETED
Status Verified Date:
2014-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Demonstrate the safety and efficacy of TipranavirRitonavir versus an active treatment regimen in highly treatment experienced Human Immunodeficiency virus 1HIV-1 infected patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None